Health Care [ 6/12 ] | Biotechnology [ 45/74 ]
NASDAQ | Common Stock
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia.
Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Reported date | EPSChange YoY | EstimateSurprise |
---|---|---|
Aug 6, 24 | -1.09 Increased by +2.68% | -0.97 Decreased by -12.37% |
May 1, 24 | -1.13 Increased by +13.74% | -1.20 Increased by +5.83% |
Feb 22, 24 | -1.39 Decreased by -10.32% | -0.88 Decreased by -57.95% |
Nov 7, 23 | -1.03 Increased by +20.16% | -0.77 Decreased by -33.77% |
Aug 1, 23 | -1.12 Increased by +31.29% | -0.44 Decreased by -154.55% |
May 15, 23 | -1.31 Increased by +28.80% | -1.63 Increased by +19.63% |
Mar 8, 23 | -1.26 Increased by +68.50% | -0.92 Decreased by -36.96% |
Nov 9, 22 | -1.29 Increased by +26.70% | -1.32 Increased by +2.27% |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Jun 30, 24 | 0.00 Decreased by N/A% | -8.23 M Decreased by -32.97% | Decreased by N/A% Decreased by N/A% |
Mar 31, 24 | 0.00 Decreased by N/A% | -8.57 M Decreased by -138.07% | Decreased by N/A% Decreased by N/A% |
Dec 31, 23 | 0.00 Decreased by N/A% | -9.02 M Decreased by -7.64% | Decreased by N/A% Decreased by N/A% |
Sep 30, 23 | 0.00 Decreased by N/A% | -7.82 M Increased by +9.00% | Decreased by N/A% Decreased by N/A% |
Jun 30, 23 | 0.00 Decreased by N/A% | -6.19 M Increased by +28.36% | Decreased by N/A% Decreased by N/A% |
Mar 31, 23 | 0.00 Decreased by N/A% | -3.60 M Increased by +63.12% | Decreased by N/A% Decreased by N/A% |
Dec 31, 22 | 0.00 Decreased by N/A% | -8.38 M Increased by +60.66% | Decreased by N/A% Decreased by N/A% |
Sep 30, 22 | 0.00 Decreased by -100.00% | -8.59 M Increased by +6.64% | Decreased by N/A% Decreased by N/A% |